MaxCyte
| MaxCyte
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
19 of 25
Similar slides by MaxCyte
See diffirences between slides (animation)
Investor Presentation
January 2024
| MaxCyte
Related slides by other companies
Berkeley Lights
Investor Day
November 2022
lights cell line development platform can address industry bottlenecks in manufacturing | Berkeley Lights
Fast Radius
SPAC
July 2021
painful product development processes | Fast Radius
Alkermes
Investor Day
March 2021
tumor targeted split advancing toward preclinical proof of concept and cell line development engineer tumor targeted subunits fused to proprietary tumor targeting antibody demonstrate that tumor targeted subunits are retained in tumors with expected kinetics demonstrate that sequentially administered subunits combine to form functional and drive dose dependent production in humanized mice complete humanization of tumor targeting antibodies ongoing characterize lead candidates and preclinical proof of concept studies planned initiate cell line development | Alkermes
SentiBio
SPAC
October 2021
multiple potential cell sources are available for clinical application | SentiBio
Other recent decks by MaxCyte
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights